Comparison of the effects of two marketed calcium preparations on reducing serum markers of bone resorption in post menopausal women

Comparison of the effects of two marketed Calcium preparations on reducing serum markers of bone resorption in post menopausal women

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000458538

Enrollment

Registered

2006-10-31

Start date

2006-11-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Calcium supplementation has been shown to reduce the incidence of osteoporosis and related fractures. Currently Calsup (calcium carbonate) is marketed widely in Australia. This study is to compare the effects of Calsup with a newer calcium supplement, Citracal (Calcium citrate) on reducing serum markers of bone resorption. The hypothesis is that citracal may be equally effective in smaller doses and would have less side effects.

Interventions

A cross over trial using Calsup (calcium carbonate) 1000 mg and Citracal (calcium citrate) 500mg given as single doses orally, one week apart following base line serum tests.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

50 Years to 55 Years

Healthy volunteers

Inclusion criteria

Post menopausal (menopause within last 5 years)

Exclusion criteria

1. renal failure, intake of calcium supplements, hypercalcaemiaany bone disorder.

Outcome results